TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research note published on Thursday, Benzinga reports. The brokerage currently has a $3.00 target price on the stock.

TransCode Therapeutics Stock Performance

NASDAQ RNAZ traded down $0.01 during mid-day trading on Thursday, hitting $0.64. The stock had a trading volume of 6,042 shares, compared to its average volume of 1,304,766. The company has a 50 day simple moving average of $0.43 and a 200 day simple moving average of $0.70. TransCode Therapeutics has a 52-week low of $0.22 and a 52-week high of $19.42.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). Sell-side analysts expect that TransCode Therapeutics will post -2.06 EPS for the current fiscal year.

Institutional Trading of TransCode Therapeutics

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC purchased a new stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned 0.84% of TransCode Therapeutics as of its most recent filing with the Securities & Exchange Commission.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.